Abstract:The results of in vitro studies indicated that ARIPIPRAZOLE, a newly developed antipsychotic, is mainly metabolized by the human cytochrome P450 isozymes CYP3A4 and CYP2D6. The objective of the present study was to investigate the influence of itraconazole (hereafter referred to as ITZ) co-administration (CYP3A4 inhibition) on the pharmacokinetics of ARIPIPRAZOLE administered to 24 healthy adult male volunteers in a fasting condition. The influence of CYP3A4 inhibition was also examined by CYP2D6 genotype. All subjects were administered a single oral dose of ARIPIPRAZOLE alone in Period I and a single oral dose of ARIPIPRAZOLE following administration of ITZ at 100 mg/day for 7 consecutive days in Period II. The pharmacokinetic parameters of ARIPIPRAZOLE and its main metabolite OPC-14857 were determined. Co-administration of ITZ increased the Cmax, AUC336 hr, and t1/2,z of ARIPIPRAZOLE and OPC-14857 by 19.4%, 48.0%, and 18.6% and by 18.6%, 38.8%, and 53.4%, respectively. By co-administration of ITZ, the CL/F of ARIPIPRAZOLE in extensive metabolizers was decreased by 26.6%, with an even greater decrease (47.3%) in intermediate metabolizers. For the co-administration period, the CL/F of ARIPIPRAZOLE in intermediate metabolizers was about half of that in extensive metabolizers. For Cmax, there was no significant difference between extensive metabolizers and intermediate metabolizers, and the percent change by co-administration of ITZ was less than 20% in both extensive metabolizers and intermediate metabolizers. For OPC-14857, the t(max) in intermediate metabolizers was longer than that in extensive metabolizers, with the difference being amplified by co-administration of ITZ. The AUC336 hr showed similar increases by co-administration of ITZ in all genotypes. The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ. The influence of CYP3A4 inhibition on the pharmacokinetics of ARIPIPRAZOLE was not considered to be clinically significant. On the other hand, definite differences in pharmacokinetics were observed between CYP2D6 genotypes.

Simultaneous Swelling and Degradation of Crosslinked Peg-Plla Networks

Effect of Nonaffine Displacement on the Mechanical Performance of Degraded PCL and Its Graphene Composites: an Atomistic Investigation

Chemical Effects in the PIXE Analysis of Fluorine

Promotion of In Vitro Osteogenic Activity by Melt Extrusion-Based PLLA/PCL/PHBV Scaffolds Enriched with Nano-Hydroxyapatite and Strontium Substituted Nano-Hydroxyapatite

Mechanisms Affecting Physical Aging and Swelling by Blending an Amphiphilic Component

Global infectious disease surveillance: getting back to basics.

Degradation-Kinetics-Controllable and Tissue-Regeneration-Matchable Photocross-linked Alginate Hydrogels for Bone Repair

Tuning structural relaxations, mechanical properties, and degradation timescale of PLLA during hydrolytic degradation by blending with PLCL-PEG

Preparation and degradation characteristics of biodegradable elastic poly (1,3-trimethylene carbonate) network

Degradation mechanisms and acceleration strategies of poly (lactic acid) scaffold for bone regeneration

Degradation behavior of 2D auxetic structure with biodegradable polymer under mechanical stress

Porous Poly(ε-caprolactone)-Poly(l-lactic acid) Semi-Interpenetrating Networks as Superior, Defect-Specific Scaffolds with Potential for Cranial Bone Defect Repair

Multiple Stimuli-response Strategy for On-demand Degradable Implants: Tannic acid-intercalated Polycaprolactone

In vitro degradation characteristics of photocrosslinked anhydride systems for bone augmentation applications

Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.

PLLA/HA Electrospin Hybrid Nanofiber Scaffolds: Morphology, In Vitro Degradation and Cell Culture Potential

Fabrication and evaluation of 3D printed poly(l-lactide) copolymer scaffolds for bone tissue engineering

Degradation Modeling of Degradable Copolymers for Biomimetic Scaffolds

Sequentially crosslinked collagen‐based hydrogel to form a semi‐interpenetrating network for enhanced stability to hydrolytic degradation and electrochemical properties

Characterization of degradation kinetics of additively manufactured PLGA under variable mechanical loading paradigms

Nanoscale β-TCP-Laden GelMA/PCL Composite Membrane for Guided Bone Regeneration